Trending...
- Athena Forge (ATFG) Introduces Advanced Token for Technology-Driven Financial Ecosystem - 114
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025 - 109
- Counseling Center of New Smyrna Beach Expands Affordable Mental Health Services for Volusia County - 102
Download
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
- JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
- Denver Welcomes Year Three of MICHELIN Guide Colorado Awards with the State's First Two Starred Restaurant, Three New One Starred Restaurants, New Recommended and Three New Special Award Winners
- Boulder Homeowners Encouraged to Paint Before Move-In for a Healthier, More Beautiful Start
- Colorado Springs: Victim identified from homicide investigation in the 1200 block of Potter Drive
- Colorado: Lt. Governor Dianne Primavera and National Jewish Health Host Long COVID Roundtable to Advance Care and Collaboration
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
- Colorado Springs: Community Notification of a Sexually Violent Predator: Larry Kaualeni Abenes
- Colorado: Host Your Holiday Celebration at The Governor's Residence at Boettcher Mansion
- Denver LASIK & Vision Correction Leader 20/20 Institute Sets New Standard for Concierge-Level Eye Surgery in Colorado
- New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
- Ananda Scientific (https://www.linkedin.com/company/ananda-scientific)
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
Filed Under: Business
0 Comments
Latest on Colorado Desk
- $ONI Listed on MEXC as ONINO Powers Europe's Tokenization Engine Into Public Platform Launch
- AZETHIO Crypto Exchange Whitepaper Reveals MPC-Secured Infrastructure Processing 1.2 Million Transactions Per Second
- CELOXFI Platform Demonstrates Advanced Security Architecture and Regulatory Framework
- Work 365 Launches PV 3.0: The Keystone Power App for Microsoft CSPs
- Local consultant shows small businesses how to turn red tape into real money
- Mayor Yemi Mobolade honors Connie Benavidez with Spirit of Colorado Springs Award
- Tour Napa Like a Local: Vines of Napa Valley Wine Passport AKA Vine Pass Unlocks Hidden Gems
- Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
- Backed by Local Launches FREE City Hubs to Empower Small Businesses in Colorado, Washington, & Oreg
- Colorado: Governor Polis Joins Governors' Call to Congress to Extend Health Care Tax Credits and Lower Costs for Families
- Colorado Leading the Way: New Study Finds Land Use Reforms, Many of Which Colorado Has Already Taken, Popular Especially Among Seniors
- Colorado: Governor Polis Releases Statement on Passing of American Icon and Actor Robert Redford
- Sloan's Lake Dental Launches New Website to Enhance Patient Experience and Access to Modern Dental Care
- Only 3 Weeks Left till the Start of the OpenSSL Conference 2025
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts